Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient
- PMID: 34009286
- DOI: 10.1093/cid/ciab392
Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient
Comment on
-
Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.Clin Infect Dis. 2022 Jan 7;74(1):24-31. doi: 10.1093/cid/ciab305. Clin Infect Dis. 2022. PMID: 33846730 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
